Most recently, noncovalent LSD1 inhibitors using a substrate-mimicking quinazoline scaffold have been evaluated as antiproliferative agents in AML, breast cancer, and rhabdomyosarcoma cell lines (104). This evidence concerns the gene KDM1A and acute myeloid leukemia.